Citations

Showing 10 of 108152 citations.

Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Richardson, Paul G. , Kumar, Shaji , Masszi, Tamás , Grząśko, Norbert , Bahlis, Nizar J. , Pour, Luděk, Baker, Bartrum W., Jackson, Sharon , Stoppa, Anne‐Marie, Gimsing, Peter , Garderet, Laurent , Laubach, Jacob P. , Cavo, Michèle , Darif, Mohamed, Labotka, Richard, Berg, Deborah, Moreau, Philippe , Kumar, Shaji K , Sandhu, Irwindeep , Touzeau, Cyrille , Laubach, Jacob P , Bahlis, Nizar Jacques , Moreau, Philippe , Masszi, Tamas , Richardson, Paul Gerard Guy , Hansson, Markus , Ganly, Peter S. , Touzeau, Cyrille , Buadi, Francis K.

Mayo Clinic

Journal of Clinical Oncology | June 11, 2021 | Volume: 39 | Issue: 22 | Pages: 2430-2442

10.1200/jco.21.00972 | PMID 34111952 Get It

PURPOSE The double-blind, placebo-controlled, phase III TOURMALINE-MM1 study demonstrated a statistically significant improvement in progression-free survival with ixazomib-lenalidomide-dexamethasone (ixazomib-Rd) versus placebo-Rd in patients with relapsed or refractory multiple myeloma. We report the final analyses for overall survival (OS). PATIENTS AND METHODS Patients were randomly assigned to ixazomib-Rd (n = 360) or placebo-Rd (n = 362), stratified by number of prior therapies (1 v 2 or 3), previous proteasome inhibitor (PI) exposure (yes v no), and International Staging System disease stage (I or II v III). OS (intent-to-treat population) was a key secondary end point. RESULTS With a median follow-up of 85 months, median OS with ixazomib-Rd versus placebo-Rd was 53.6 versus 51.6 months (hazard ratio, 0.939; P = .495). Lower hazard ratios, indicating larger magnitude of OS benefit with ixazomib-Rd versus placebo-Rd, were seen in predefined subgroups: refractory to any (0.794) or last (0.742) treatment line; age > 65-75 years (0.757); International Staging System stage III (0.779); 2/3 prior therapies (0.845); high-risk cytogenetics (0.870); and high-risk cytogenetics and/or 1q21 amplification (0.862). Following ixazomib-Rd versus placebo-Rd, 71.7% versus 69.9% of patients received ≥ 1 anticancer therapy, of whom 24.7% versus 33.9% received daratumumab and 71.8% versus 76.9% received PIs (next-line therapy: 47.5% v 55.8%). Rates of new primary malignancies were similar with ixazomib-Rd (10.3%) and placebo-Rd (11.9%). There were no new or additional safety concerns. CONCLUSION Median OS values in both arms were the longest reported in phase III studies of Rd-based triplets in relapsed or refractory multiple myeloma at the time of this analysis; progression-free survival benefit with ixazomib-Rd versus placebo-Rd did not translate into a statistically significant OS benefit on intent-to-treat analysis. OS benefit was greater in subgroups with adverse prognostic factors. OS interpretation was confounded by imbalances in subsequent therapies received, especially PIs and daratumumab.
Real-world evidence for carfilzomib dosing intensity on overall survival and treatment progression in multiple myeloma patients
Medhekar, Rohan , Panjabi, Sumeet , Hines, Dionne M. , Wang, Xin, Iskander, Karim, Welliver, Tim, Wade, Rolin L. , Wang, Xin , Raje, Noopur , Ailawadhi, Sikander

Mayo Clinic

Journal of Oncology Pharmacy Practice | June 11, 2021 | Volume: 28 | Issue: 5 | Pages: 1130-1139

10.1177/10781552211015283 | PMID 34111994 Get It

Introduction Carfilzomib dosing as a single agent or in combination with dexamethasone (Kd) has evolved from the initial 27 mg/m 2 twice-weekly (legacy dose), to more recently approved doses of 56 mg/m 2 twice-weekly and 70 mg/m 2 once-weekly (optimized doses). The objective of this study was to evaluate the overall survival (OS), and time to next treatment (TTNT) among multiple myeloma patients treated with Kd optimized vs legacy doses. Methods A retrospective analysis of patients receiving Kd between 01/01/2013–07/31/2017 was conducted using IQVIA’s oncology electronic medical records database. Kd dose was estimated based on body surface area. OS was measured from the Kd-initiation date until death. TTNT was defined as the time from Kd-initiation until the start of subsequent treatment. Kaplan-Meier analysis and Cox models were used to evaluate OS and TTNT. Results Of the 1,469 patients evaluated, 129 (8.8%) received optimized dose and 1,340 (91.2%) received legacy dose. Risk of mortality was 64% lower for patients receiving the optimized doses (HR: 0.36, 95% CI: 0.178–0.745). Patients receiving the optimized doses had significantly longer TTNT compared to patients receiving the legacy dose (median TTNT: 17.5 months [95% CI: 14.8-NE] and 13.2 months, [95% CI: 12.4–14.4], respectively; p = 0.023), and 33% lower risk of progressing to the subsequent treatment (HR: 0.67, 95% CI: 0.48–0.93). Conclusions Patient outcomes could be improved if eligible MM patients are treated with the optimized, recently approved Kd doses (56 mg/m 2 twice-weekly and 70 mg/m 2 once-weekly).
Belantamab mafodotin detection by MASS-FIX and immunofixation
Mellors, Patrick , Kohlhagen, Mindy , Dasari, Surendra , Kumar, Shaji , Lacy, Martha Q. , Murray, David , Mellors, Patrick W , Kohlhagen, Mindy C, Willrich, Maria A V, Murray, David L., Dispenzieri, Angela , Willrich, Maria Alice V. , Gertz, Morie A. , Dispenzieri, Angela

Mayo Clinic

Clinical Chemistry and Laboratory Medicine (CCLM) | June 11, 2021 | Volume: 59 | Issue: 11 | Pages: e430-e433

10.1515/cclm-2021-0326 | PMID 34114387 Get It

Return to Sports After Primary Reverse Shoulder Arthroplasty: Outcomes at Mean 4-Year Follow-up
Mara, Kristin C. , Tangtiphaiboontana, Jennifer , Jensen, Andrew R, Sanchez-Sotelo, Joaquin, Mara, Kristin C , Jensen, Andrew R. , Camp, Christopher L. , Morrey, Mark E. , Sánchez‐Sotelo, Joaquín

Mayo Clinic

Orthopaedic Journal of Sports Medicine | June 10, 2021 | Volume: 9 | Issue: 6 | Pages: No page available

10.1177/23259671211012393 | PMID 34179208 Get It

Background: With the expanding use of reverse shoulder arthroplasty (RSA) to treat various shoulder conditions, there has been a rise in the number of RSAs performed, especially in physically active patients. Limited information regarding sports after RSA is available to properly counsel patients on postoperative expectations. Purpose: To assess the rate of return to sports as well as the ability to return to the same level of preoperative intensity, frequency, and duration of sport after primary RSA. Study Design: Case series; Level of evidence, 4. Methods: This was a retrospective review of patients who underwent primary RSA at our institution between 2014 and 2016. Shoulder motion, Subjective Shoulder Value score, American Shoulder and Elbow Surgeons score, pre- and postoperative sports activities, and barriers to return to sport were assessed in 109 patients after RSA (93 patients with unilateral RSA and 16 patients with bilateral RSA). The mean age at the time of surgery was 70 years (range, 34-86 years), with a mean follow-up of 3.9 years (range, 2-12 years). Results: The mean rate of return to sports was 70.1% (range, 0%-100%). There was no difference in return to sports between those with uni- and bilateral RSA ( P = .64). Fishing, swimming, elliptical/treadmill, and hunting were the most common sports after RSA with return rates of 91%, 73%, 86%, and 82% respectively. A majority of patients returned to the same level of preoperative intensity, frequency, and duration for all sports except for climbing and swimming. There was a lower mean rate of return for high-demand sports (62.9%) compared with low- and medium-demand sports (76.7%) ( P = .005). The most common reasons for inability to return to sports included limited motion, fear of injury, and weakness. Conclusion: Patients who had undergone primary uni- or bilateral RSA reported a 70.1% rate of return to sports with maintenance of the same level of intensity, duration, and frequency of preoperative sport participation. Rates of return to high-demand sports were lower than low- and medium-demand sports. Patients also had difficulty returning to overhead sports.
Regional analgesia in cardiac anesthesia: Welcoming a new era in perioperative pain management
Yu, Soojie , Aljure, Oscar , Aljure, Oscar D

Mayo Clinic

Journal of Cardiac Surgery | June 10, 2021 | Volume: 36 | Issue: 8 | Pages: 2824-2825

10.1111/jocs.15667 | PMID 34110056 Get It

IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers
Vandergaast, Rianna , Reiter, Samantha , Lathrum, Chase , Lech, Patrycja, Gnanadurai, Clement W., Haselton, Michelle, Buehler, Jason , Narjari, Riya , Schnebeck, Luke, Roesler, Anne, Sevola, Kara , Suksanpaisan, Lukkana , Bexon, Alice, Naik, Shruthi , Brunton, Bethany, Rafael, Grace, Tran, Sheryl, Baum, Alina , Kyratsous, Christos A. , Peng, Kah Whye, Russell, Stephen J. , Russell, Stephen J , Vandergaast, Rianna , Carey, Timothy S. , Weaver, Scott C

Mayo Clinic

mSphere | June 10, 2021 | Volume: 6 | Issue: 3 | Pages: No page available

10.1128/msphere.00170-21 | PMID 34077262 Get It

Since its emergence at the end of 2019, SARS-CoV-2, the causative agent of COVID-19, has caused over 100 million infections and 2.4 million deaths worldwide. Recently, countries have begun administering approved COVID-19 vaccines, which elicit strong immune responses and prevent disease in most vaccinated individuals.
Gastroesophageal Junction Fat Pad Tissue from Obese Patients Impairs Esophageal Epithelial Barrier Function and Disrupts Cell‐to‐Cell Connections
Paris, Sheré , Ekeanyanwu, Rebecca, Davis, Daniel, Whelan, Kelly A. , Iyer, P. K. R., Katzka, David A. , Podgaetz, Eitan , Leeds, Steven G. , Zhang, Xi , Souza, Rhonda, Iyer, Prasad, Ward, Marc A. , Spechler, Stuart Jon

Mayo Clinic

The FASEB Journal | June 10, 2021 | Volume: 35 | Issue: S1 | Pages: No page available

10.1096/fasebj.2021.35.s1.02126 Get It

Introduction Visceral obesity is associated with GERD and, traditionally, it has been assumed that visceral fat predisposes to GERD primarily by increasing intra‐abdominal pressure. However, transmission electron microscopy (TEM) of esophageal biopsies from obese individuals without GERD exhibit dilated intercellular spaces (DIS) and, in earlier studies, we found that substances secreted by mature adipocytes in visceral fat from obese patients impair esophageal epithelial barrier function, induce DIS and reduce transepithelial resistance (TER). There is a fat pad at the gastroesophageal junction (GEJ) that is in intimate contact with the distal esophagus. We now explore whether whole GEJ fat tissue of obese individuals secretes substances that impair esophageal barrier function. Methods We obtained GEJ fat from 3 obese (BMI 46, 60, 74) and 3 non‐obese (BMI 24, 26, 27) patients having foregut surgery. Human esophageal squamous cells were seeded into transwells and grown to confluence for 3 days. On day 4, cells were raised to an air‐liquid interface (ALI) to allow for differentiation, stratification, and esophageal barrier formation. ALI cultures were exposed to conditioned media (CM) from GEJ fat or to control medium beginning at day 4. TER was measured on days 4, 6, and 8 using the EVOM2 Epithelial Volt/Ohm Meter. On day 8, ALI cultures were stained with H&E and Ki‐67 and imaged; barrier permeability was assessed by a biotinylation reagent applied to the ALI surface. TEM of ALIs and of esophageal biopsies from 2 non‐obese and 2 obese patients without GERD were assessed. Results CM from all 3 obese patients significantly reduced TER on days 6 and 8; CM from 2 non‐obese patients did not reduce TER whereas CM from 1 non‐obese patient induced a slight reduction in TER at day 8 (Table 1). Marked DIS were found only in ALI cultures grown with CM from obese patients. In ALIs grown with CM from non‐obese patients, the biotinylation reagent stopped at the superficial layers of esophageal cells. In contrast, the biotinylation reagent diffused through all cell layers in ALIs grown with obese patient CM. Increases in basaloid cells and in Ki‐67 were found in ALIs grown with obese patient CM. TEMs of ALIs grown with non‐obese patient CM demonstrated well‐oriented cell‐cell junctions similar to TEMs of non‐obese patient esophageal biopsies. In contrast, ALIs grown with obese patient CM demonstrated cell‐cell junctional structures that were disorganized, aggregated, and floating within the DIS, similar in appearance to TEMs of the obese patients’ esophageal biopsies. Conclusion Substances produced by GEJ fat of obese patients impair esophageal epithelial barrier integrity, cause basal cell hyperplasia and DIS, and disrupt intercellular connections. These findings in ALI cultures recapitulate abnormalities seen by TEM in esophageal biopsies of obese patients.
Structural and Computational Investigations of an Autoinhibitory Loop in Human Mesorypsin
Coban, Matt , Caulfield, Thomas R. , Radisky, Evette S.

Mayo Clinic

The FASEB Journal | June 10, 2021 | Volume: 35 | Issue: S1 | Pages: No page available

10.1096/fasebj.2021.35.s1.02942 Get It

There is evidence in the literature that many serine proteases, as typified by thrombin, possess an autoinhibitory loop (AIL) that controls substrate access to the active site. The presence of an AIL has not been documented in trypsins. Mesotrypsin is a human trypsin implicated in tumor cell invasiveness for pancreatic and other cancers. However, it is a challenging therapeutic target because of high structural similarity to other trypsin‐like serine proteases, typically lower affinity for inhibitors compared to related serine proteases, and unique ability to cleave proteinaceous serine protease inhibitors. We have recently solved a high‐resolution crystal structure of unbound mesotrypsin which revealed that residues 215‐220 partially occluded the substrate binding site. Comparison of this new structure with previous inhibitor‐bound crystal structures of mesotrypsin demonstrate the conformational transition of the AIL between closed and open states. These two conformational states were investigated with molecular dynamics simulations to discern the dynamical behavior of the AIL in different conformations. The AIL has increased local dynamics in the closed position, as well as a larger number of conformational clusters; this suggests there is a more well‐defined open state ready to accept substrate, while there are a dynamic variety of closed states that preclude substrate binding to various extents. Additionally, we identified novel binding sites that are exposed by the conformational shift of the AIL to the closed state. We have conducted initial in silico screening for compounds predicted to bind preferentially to the AIL closed (but not open) structure and stabilize the closed conformation. These efforts have resulted in more than 40 compounds as initial hits. Exploiting the AIL as a novel allosteric binding site represents a new mechanism for targeting mesotrypsin and preventing its protumorigenic function.
Variable GILT protein expression in melanoma cells of metastatic tumor specimens
Adams, Anngela C. , Thomson, Nick, Roe, Denise J. , DiCaudo, David J. , Homsi, Jade , Cui, Haiyan , Hastings, Karen Taraszka

Mayo Clinic

The FASEB Journal | June 10, 2021 | Volume: 35 | Issue: S1 | Pages: No page available

10.1096/fasebj.2021.35.s1.00315 Get It

Melanoma is the sixth most common cancer in the US. Immunotherapies, such as anti‐CTLA‐4 and anti‐PD‐1, have transformed the treatment of advanced melanoma; however, a subset of patients fail to respond to immunotherapy. Thus, improved predictors of the anti‐melanoma immune response and response to immunotherapy are needed. We have previously shown that 1) gamma‐interferon‐inducible lysosomal thiol reductase (GILT) is critical for MHC class II‐restricted presentation of a melanoma antigen, 2) there is variable GILT protein expression in melanoma cells from primary and cutaneous metastatic melanoma specimens, and 3) high GILT mRNA expression in melanoma specimens is associated with improved overall survival. Here, we created a database of n = 43 metastatic melanoma patients (stage III or IV) annotated with clinical outcome. Formalin‐fixed, paraffin‐embedded sections of pre‐treatment metastatic melanoma specimens were tested for GILT protein expression using immunohistochemistry and scored by a dermatopathologist and dermatologist. GILT expression in melanoma cells was detected in 65% of lymph node and distant organ metastases, consistent with our prior finding of GILT expression in 58% of cutaneous metastases. The frequency of GILT‐staining melanoma cells was determined by the ratio of the area of tumor cells with positive GILT staining to the total area of tumor cells. The frequency of GILT‐staining melanoma cells among specimens with positive GILT staining was 15.2% ± 24.7% (mean ± SD). The median frequency of GILT staining was used to divide the patients into no/low and high GILT expression groups. The median overall survival was 52.8 months in the no/low GILT expression group, while the median overall survival was not reached in the high GILT expression group (log‐rank, p = 0.67). For the n = 34 patients who were treated with immunotherapy targeting CTLA‐4 and/or PD‐1, the median overall survival was 38.2 months in the no/low GILT expression group, while the median overall survival was not reached in the high GILT expression group (log‐rank, p = 0.83). These data suggest that high GILT expression in melanoma cells may be associated with improved overall survival, although a statistically significant association of GILT with survival was not observed in the whole group or the subset of patients treated with immunotherapy. A limitation of the current analysis is that 65% of patients have incomplete clinical outcome data. This study demonstrates variable GILT protein expression in tumor cells in metastatic melanoma specimens. Updated clinical outcome data will allow us to better evaluate the association of GILT protein expression in melanoma cells with overall survival and response to immunotherapy in metastatic melanoma patients.
KLF11 deficiency exacerbates renal damage in experimental unilateral ureteral obstruction
Grande, Joseph P. , Lorenzo, Silvana De

Mayo Clinic

The FASEB Journal | June 10, 2021 | Volume: 35 | Issue: S1 | Pages: No page available

10.1096/fasebj.2021.35.s1.05267 Get It

KLFs (Kruppel‐like factors) comprise a family of over 17 distinct transcription factors that have been shown to regulate cell metabolism and renal function, including podocyte differentiation and maintenance of the glomerular filtration barrier. In non‐renal systems, KLF11 has been shown to regulate fibrosis. However, no previous studies have established a potential role for KLF11 in renal pathophysiology. We sought to test the hypothesis that KLF11 regulates renal fibrosis in unilateral ureteral obstruction, a well‐established murine model of renal fibrosis. Mice with homozygous deletion of the KLF11 gene (KO) and wild‐type (WT) mice were subjected to unilateral ureteral obstruction (UUO; n=8 per group); sham controls (n=4 per group) were subjected to manipulation of the ureter without ligation. Kidneys were harvested at 9 days following surgery,. Semiquantitative histopathologic analysis of interstitial fibrosis, tubular atrophy, and interstitial inflammation was performed in a blinded fashion. Analysis of gene expression was performed on renal cortex using Pathway Detect RNA arrays and by RNASeq. Histopathologic analysis of sham controls revealed no significant alterations. However, expression of several elements of the TGF‐beta signaling pathway was significantly higher in KLF11 KO sham mice, compared to WT mice, including TGF‐beta receptors type I and type II, Smad2, Smad 7, Bmpr1B, and Bmpr2R, and the KLF‐related transcription factor Sp1 (all p<0.05). In mice subjected to UUO, interstitial fibrosis, tubular atrophy, and interstitial inflammation were significantly greater in KLF11 KO mice compared to WT mice. Interstitial inflammation was associated with influx of alternatively activated macrophages, as assessed by quantitative analysis of CD206+ infiltrating cells (p<0.05); no significant increase in CD3+ T cell numbers were noted. Expression of several members of the TGF‐beta signaling pathway were significantly increased in KLF11 KO UUO mice, compared to WT UUO mice, including TGF‐beta 1, TGF‐beta‐2, and TGF‐beta3, TGF‐beta receptors type I and type II, and Smad 1,2,3,4, and 5 (all p<0.05). Conversely, expression of the transcription factor JunB was markedly increased in WT UUO mice compared to WT sham mice (12.2 ‐fold; p<0.0001). However, JunB expression was markedly decreased in KLF11 KO mice (both sham and UUO). Although MMP expression was not significantly different in KO versus WT mice, TIMP3 expression was higher in KO mice compared to WT mice. In conclusion, we found that renal damage is exacerbated in KLF11 KO mice subjected to UUO, compared to WT UUO mice and is associated with influx of potentially pro‐fibrotic, alternatively activated M2 macrophages. KLF11 appears to be a critical regulator of TGF‐beta signaling, as KLF11 deficiency is associated with increased expression of TGF‐beta and signaling intermediates of this fibrogenic pathway.